Susquehanna International Group, LLP Bio Xcel Therapeutics, Inc. Transaction History
Susquehanna International Group, LLP
- $641 Billion
- Q4 2024
A detailed history of Susquehanna International Group, LLP transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 34,531 shares of BTAI stock, worth $82,183. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,531
Previous 34,207
0.95%
Holding current value
$82,183
Previous $20,000
40.0%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding BTAI
# of Institutions
52Shares Held
8.63MCall Options Held
34.5KPut Options Held
59.4K-
Armistice Capital, LLC New York, NY4.32MShares$10.3 Million0.02% of portfolio
-
Ubs Group Ag1.28MShares$3.04 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.19MShares$2.83 Million0.0% of portfolio
-
Black Rock Inc. New York, NY441KShares$1.05 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA312KShares$742,4760.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $66.7M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...